Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pre-Operative Education in Breast Surgery, A Quality Improvement Project.

European journal of breast health·2026

Same author

Human Epidermal Growth Factor Receptor 2 (HER2/Neu)-Positive Ovarian High-Grade Serous Carcinoma Metastasizing to the Breast: A Case Report.

Cureus·2025

Same author

Neoadjuvant Versus Adjuvant Therapy for Metaplastic Breast Cancer: Insights from the National Cancer Database-Is There a Winning Strategy?

Annals of surgical oncology·2025

Same author

Management of Isolated Axillary Recurrence in Breast Cancer: Is There a Role for Targeted Axillary Dissection?

Cureus·2025

Same author

Fibromatosis of the breast: a case report and literature review.

AME case reports·2025

Same author

ASO Visual Abstract: The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer.

Annals of surgical oncology·2024

Search research articles

Related Experiment Video

Updated: May 11, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Triple-Negative Metaplastic Breast Cancer Ameliorated Following KEYNOTE-522: A Case Report.

Edoardo G Frezza¹, Gayatri D Nimmagadda², Olutayo Sogunro³

¹Medicine, Trinity School of Medicine, Baltimore, USA.

|August 27, 2025

Summary

Metaplastic breast cancer (MpBC), a rare and aggressive subtype, often resists treatment. A triple-negative MpBC case showed a complete response to chemotherapy plus pembrolizumab immunotherapy, offering hope for improved outcomes.

Keywords:

breast cancer cardiac sarcoidosis (cs)keynote 522 metastatic metaplastic breast cancer triple-negative breast carcinoma

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Related Experiment Videos

Last Updated: May 11, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Area of Science:

Oncology
Immunotherapy
Breast Cancer Research

Background:

Metaplastic breast cancer (MpBC) is a rare, aggressive subtype, with triple-negative MpBC (TN-MpBC) exhibiting poor response to conventional therapies.
Standard treatments offer limited efficacy for TN-MpBC, necessitating novel therapeutic approaches.

Observation:

A 48-year-old African American female presented with incidentally diagnosed, high-grade TN-MpBC (5.8 cm, Ki-67 >30%).
The patient received neoadjuvant chemotherapy (paclitaxel, carboplatin, doxorubicin, cyclophosphamide) combined with pembrolizumab immunotherapy (KEYNOTE-522 regimen).

Findings:

Significant tumor regression was observed post-treatment.
Bilateral mastectomy revealed a complete pathological response with no residual malignancy.
Adjuvant therapy includes pembrolizumab and proton radiation therapy.

Implications:

This case highlights the potential efficacy of chemoimmunotherapy, specifically the KEYNOTE-522 regimen, in treating TN-MpBC.
The positive response in a PD-L1 expressing tumor supports immunotherapy's role in improving TN-MpBC prognosis.
Further research into targeted strategies for TN-MpBC is crucial.